279 related articles for article (PubMed ID: 32601947)
1. The Role of Neoadjuvant Therapy in Melanoma.
Kelly ZR; Gorantla VC; Davar D
Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Pelster MS; Amaria RN
Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
Davar D; Tarhini AA; Kirkwood JM
Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad M; Tarhini AA
Curr Oncol Rep; 2023 Apr; 25(4):325-339. PubMed ID: 36781621
[TBL] [Abstract][Full Text] [Related]
5. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Menzies AM; Amaria RN; Rozeman EA; Huang AC; Tetzlaff MT; van de Wiel BA; Lo S; Tarhini AA; Burton EM; Pennington TE; Saw RPM; Xu X; Karakousis GC; Ascierto PA; Spillane AJ; van Akkooi ACJ; Davies MA; Mitchell TC; Tawbi HA; Scolyer RA; Wargo JA; Blank CU; Long GV
Nat Med; 2021 Feb; 27(2):301-309. PubMed ID: 33558722
[TBL] [Abstract][Full Text] [Related]
6. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
Amaria RN; Menzies AM; Burton EM; Scolyer RA; Tetzlaff MT; Antdbacka R; Ariyan C; Bassett R; Carter B; Daud A; Faries M; Fecher LA; Flaherty KT; Gershenwald JE; Hamid O; Hong A; Kirkwood JM; Lo S; Margolin K; Messina J; Postow MA; Rizos H; Ross MI; Rozeman EA; Saw RPM; Sondak V; Sullivan RJ; Taube JM; Thompson JF; van de Wiel BA; Eggermont AM; Davies MA; ; Ascierto PA; Spillane AJ; van Akkooi ACJ; Wargo JA; Blank CU; Tawbi HA; Long GV
Lancet Oncol; 2019 Jul; 20(7):e378-e389. PubMed ID: 31267972
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract][Full Text] [Related]
10. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
Staeger R; Martínez-Gómez JM; Turko P; Ramelyte E; Kraehenbuehl L; Del Prete V; Hasan Ali O; Levesque MP; Dummer R; Nägeli MC; Mangana J
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473216
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
Ferraresi V; Vari S
Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.
Rhodin KE; Gaughan EM; Raman V; Salama AK; Hanks BA; Shah R; Tyler DS; Slingluff CL; Beasley GM
Ann Surg; 2023 Jun; 277(6):e1306-e1312. PubMed ID: 35797609
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
Long GV; Menzies AM; Scolyer RA
J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
[TBL] [Abstract][Full Text] [Related]
15. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.
van Akkooi ACJ; Blank C; Eggermont AMM
Eur J Cancer; 2023 Mar; 182():38-42. PubMed ID: 36738540
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
[TBL] [Abstract][Full Text] [Related]
17. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC; Luke JJ
Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
[TBL] [Abstract][Full Text] [Related]
18. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for stage II melanoma: the need for further studies.
Lee R; Mandala M; Long GV; Eggermont AMM; van Akkooi ACJ; Sandhu S; Garbe C; Lorigan P
Eur J Cancer; 2023 Aug; 189():112914. PubMed ID: 37301717
[TBL] [Abstract][Full Text] [Related]
20. The extent of surgery for stage III melanoma: how much is appropriate?
Franke V; van Akkooi ACJ
Lancet Oncol; 2019 Mar; 20(3):e167-e174. PubMed ID: 30842060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]